$7.24
▼ -0.1% Today
as of Aug 5, 16:50 ET
Last 30 days
Recent Press Releases & News
IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake
Pfizer, Merck, Amgen Double Down On Cancer And Send Takeover Buzz Around SLS And IBRX Into Overdrive
IBRX Founder Soon-Shiong Bets On Anktiva's Next Growth Phase — ImmunityBio Posts Record Q2 Sales
Overview
52-week range
$1.95
$12
50% of range
Avg surprise (last 3)
-12.5%
Avg reaction (last 2)
+3.3%
50% positive
Latest IV / EM
93%
EM ±5.5% · $8 · Aug 7
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.09 | $-0.08 | -12.5% | +40.0% | -7.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.07 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $-0.10 | $-0.10 | 0.0% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-0.15 | $-0.12 | -25.0% | — | +14.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.14 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.20 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.20 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.19 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.32 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $44M | — | $32M | $26M | $17M | — | $6M | $1M |
| Cost of revenue | $238,000 | — | $177,000 | $136,000 | $58,000 | — | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-70M | — | $-56M | $-71M | $-64M | — | $-80M | $-99M |
| Net income | $-633M | — | $-67M | $-93M | $-130M | — | $-86M | $-135M |
| EPS (diluted) | $-0.62 | — | $-0.07 | $-0.10 | $-0.15 | — | $-0.14 | $-0.20 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $205M | $88M | $60M | $138M | $61M | $143M | $112M | $130M |
| Inventory | $547,000 | $910,000 | $7M | $7M | $8M | $8M | $2M | $2M |
| Total current assets | $453M | $315M | $329M | $208M | $109M | $185M | $163M | $243M |
| Total assets | $647M | $502M | $519M | $402M | $304M | $383M | $365M | $444M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $1.52B | $1.00B | $1.04B | $972M | $894M | $871M | $1.11B | $1.14B |
| Total equity | $-870M | $-500M | $-524M | $-571M | $-591M | $-489M | $-745M | $-698M |